Latest news with #ThePlazaHotel
Business of Fashion
14 hours ago
- Business
- Business of Fashion
Is Sailing Ready for Its Fashion Moment?
Last weekend, nearly 10,000 people packed a grandstand in New York for this year's kickoff of SailGP, an international sailing race often likened to Formula 1 on the water that has rapidly attracted audiences with its elite, globetrotting allure. At the top of every sail on the high-speed catamarans was the logo for Rolex, which has sponsored the race since its start in 2019. This year, L'Oréal was also featured on the French team's sail as part of its three-year sponsorship deal with the team, while Tommy Hilfiger claimed nearly the entire sail of the US team, which it also outfitted on and off the water. On the ground, however, it was a different story. Fashion and beauty were largely absent, with most of the brand activations coming from hospitality players like The Plaza Hotel and Nobu. The event showed early hints of how fashion and beauty are starting to take notice of SailGP, but also how much room there is to grow. 'It's the very beginning,' said Christophe Babule, L'Oréal's chief financial officer. 'Look at Formula 1 30 years ago. It was a much more confidential event. Today, it's a worldwide event with a huge [following], so I'm quite sure that we will see more and more players coming into this event in the near future.' While it's early to crown SailGP the next Formula 1 for brands, the sport is seeing success in attracting a wider range of viewers, many of whom are drawn in by its aspirational nature. At its Auckland race, for instance, 70 percent of viewers had never sailed before. SailGP is also the subject of a new Paramount+ docuseries released today, 'SailGP: Uncharted,' that should bring it even more exposure, and as in other sports, high-profile investors have been getting involved with the teams, which may help with driving visibility. Anne Hathaway has joined the ranks of investors backing the Italian team, while Ryan Reynolds and Hugh Jackman bought the Australian team, following Reynolds' investment in English football team Wrexham A.F.C. alongside co-owner Rob McElhenney, which has turned into a sensation with the series 'Welcome to Wrexham.' 'Our challenge is education and marketing to new eyeballs,' said Mike Buckley, co-owner and chief executive of the US SailGP team. SailGP has been promoting itself to an affluent fan base at events like the Tribeca Film Festival, as well as the Las Vegas Grand Prix to tap racing fans more broadly. While sponsors of SailGP were traditionally more specific to sailing, like Helly Hansen and Sail Racing, the shift creates an opportunity for brands outside of the performance gear space. 'Our audience is an audience that I think high end fashion brands would resonate with, in terms of our demographic that are either coming to our events or watching on TV or a small screen,' said SailGP managing director Andrew Thompson. Storytelling Through Sailing SailGP's Paramount+ series has its brand partners banking on enhanced visibility. The fast-paced nature of the event set against backdrops from Saint-Tropez to Dubai is eye candy for today's short attention spans. 'It is obvious that it will work, because it's pretty well designed to be seen on a screen,' said Babule from L'Oréal. 'We know what it takes today to activate consumers. These races are very quick ones, so you can follow that on Instagram or on TV.' Beyond the show, content production opportunities for brand partners are plentiful. For Tommy Hilfiger, being easily visible on the boat and at the heart of the sport is crucial. 'With SailGP, we chose a place where one of the key athletes sits to play a pivotal role in steering and maneuvering the boat,' said Virginia Ritchie, the brand's chief marketing officer. 'So we get a lot of great content of him sitting right on top of the flag.' In addition to designing the team uniform, as well as performance goggles in partnership with Safilo, the brand dresses the team in fashion outside of the performance realm for moments like walking to the race, or for event appearances, said Ritchie — all of which can easily be repurposed as content across brand channels. The company sees a significant opportunity for driving fashion sales through storytelling that uses sailing and performance content. To accompany the launch of its spring 2025 sailing capsule collection, its window displays in key European stores used photos from the Los Angeles and San Francisco races featuring its branded red, white and blue flag. Rolex has leaned into storytelling around SailGP athletes. It produced a series featuring the British SailGP team's strategist Hannah Mills and showcasing her career and journey becoming a mother and then returning to the team. The sport also gives brands an opportunity to position themselves in a new light with customers. L'Oréal, for instance, is hoping to reach more men, who are historically more challenging to sell on beauty. They make up 'probably 25 percent of beauty consumption, but actually 10 percent of our sales,' said Babule. 'When you are in a sport like high-tech sailing, it's a way to more easily reach a new target of consumers that is in the clear objective that we set ourselves.' The group can activate differently depending on where the races occur, varying the brands it features and marketing tactics it employs. Education around suncare, for instance, remains a challenge for L'Oréal in the European market, and activating around sailing moments, where sun exposure is an obvious element of the sport, creates chances for the group's dermatological beauty division to further its goals in the region. Brand Alignment For brands considering potential sports partnerships, however, alignment with the sport is a key consideration. Tommy Hilfiger, for instance, landed on SailGP after looking at seven potential sports to work with. Sailing was one of them — and a natural fit, too, due to how influential the sport was to the formation of the brand's DNA, all the way down to the Tommy Hilfiger flag, which is based on the nautical letters (colourful flags used in sailing to represent different letters in the alphabet) for the designer's initial, T J H, said Ritchie. The brand also launched its first Sailing Gear collection in the early 1990s. Tommy Hilfiger's experience as an F1 partner let it see that it had another opportunity to marry brand history, a similar racing product and the chance to work closely with athletes in the way that Tommy Hilfiger had with racecar drivers Lewis Hamilton and George Russell, transforming the paddock walk, which had been very 'uniform driven,' into a runway of sorts, Ritchie said. 'That kicked off a ton of collaboration opportunities, a whole new content stream and storytelling,' said Ritchie. L'Oréal has its own history in sailing. The company has been involved with a number of sailing races, including sponsoring the French team when women could compete in the America's Cup for the first time in 2024, as part of the group's broader goal of supporting women. SailGP, which is the only sailing race to include both men and women on the same boat, fell squarely into L'Oréal's value system. While Rolex has historically been involved with sailing — it first partnered with the New York Yacht Club, which created the America's Cup, in 1958 — SailGP, a more modern version of the sport, 'is not their traditional sailing property,' said Thompson. When the brand came on board as SailGP's title sponsor when the race first launched, 'For them, it was quite a bold move,' Thompson added. 'We were untested. [But] Rolex saw the opportunity.'
New York Post
21-05-2025
- Entertainment
- New York Post
Glenn Howerton on 'Sirens,' why he likes playing 'lunatics'
He's going from the D.E.N.N.I.S. system to the beach. Glenn Howerton, best known for starring in 'It's Always Sunny in Philadelphia,' co-stars in the new Netflix miniseries 'Sirens' (premiering May 22). 'I had never read anything quite like this script, tonally. It's like a suspenseful drama, but it's also really funny,' Howerton, 49, exclusively told The Post. Advertisement The plot follows Devon (Meghann Fahy, 'The White Lotus'), who thinks her sister, Simone (Milly Alcock, 'House of the Dragon') needs to be rescued from her new job. Simone has been working for the wealthy socialite Michaela Kell (Julianne Moore) who Devon thinks is running a cult at her lavish beach estate. Kevin Bacon co-stars as Michaelas's husband Peter, and Howerton plays their friend and Simone's boyfriend, Ethan. 6 Glenn Howerton, Milly Alcock, and Meghann Fahy in 'Sirens.' Advertisement 6 Glenn Howerton attends the Netflix Premiere of Sirens at the Paris Theater on May 20, 2025 in New York City. Getty Images for Netflix '[Ethan is] so different from so many characters I play,' Howerton explained. '[But] he has an element of other characters I play. He's not a slob. He's a well put together rich dude, which is a little bit typecasting for me.' Ethan isn't fundamentally a bad person, despite being, 'a bit naive and oblivious at times,' the actor continued. 'I'm always getting cast as raving lunatics and maniacs, so it's nice to do something different, every once in a while.' Howerton has previously appeared on 'The Mindy Project,' 'Fargo,' and 'Blackberry,' and has played sociopathic Dennis Reynolds on 'It's Always Sunny' since its 2005 debut. Advertisement 'I do think a lot of actors enjoy playing things that are very different from themselves, and having the opportunity to – as Dennis would put it – wear another man's skin,' he quipped. 6 Charlie Day as Charlie, Rob McElhenney as Mac, Glenn Howerton as Dennis, Kaitlin Olson as Dee, Danny DeVito as Frank in 'It's Always Sunny In Philadelphia.' 6 Glenn Howerton attends Netflix's 'Sirens' World Premiere at The Plaza Hotel on May 20, 2025 in New York City. FilmMagic 6 Meghann Fahy, Felix Solis, Julianne Moore, Josh Segarra, Milly Alcock and Glenn Howerton attend the world premiere of Netflix's 'Sirens' at The Plaza Hotel on May 20, 2025 in New York City. WireImage Advertisement 'For me, there's something cathartic about portraying characters that behave in a way that I would never behave. And getting to just be selfish and narcissistic and a bit of a jerk and just yell at people,' Howerton continued. 'I strive to be a good person in my real life, so it's fun to be bad. And I find them funny and sad and sort of pathetic — narcissists — and people that walk into the world not thinking about how their actions impact other people. I think it's a bit sad and definitely frustrating. So I like to send it up in a satirical way.' Since Howerton is 49 and Alcock is 25, their 'Sirens' characters are in an age-gap romance. 'That's just what it is in the story, so I approached that situation the way I would approach any similar situation, regardless of the person's age – with a lot of communication and respect on set, to make sure we're all on the same page with how we shoot the scenes,' he explained. 6 -Milly Alcock and Julianne Moore in 'Sirens.' 'Milly is just a consummate professional, it was a lot of fun.' As for his other co-star, Julianne Moore, he gushed: 'She's so cool.' Advertisement 'I think she's aware enough of her status within the business to want to put people at ease, as quickly as possible. She's possibly had experiences in the past where people were maybe intimidated to be around her, because she plays such powerful characters often, and she has such a powerful glowing presence.' It would be 'easy' to be intimidated by her, 'but she knocks those things down pretty quickly and is just a very grounded and wonderful person and a lot of fun to hang out with between scenes,' he concluded. 'She's not just there to be a giant movie star, she's a real artist.'
Newsweek
12-05-2025
- Entertainment
- Newsweek
Psychopaths Are More Attractive, Study Warns
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Dark personalities may not just be uncaring, self-obsessed and skilled at manipulation—but they may also look trustworthy, according to a new study that sheds light on how physical appearance can subtly disarm our instincts. A new study published in the journal Personality and Individual Differences examined how people perceive strangers' trustworthiness based on facial appearance alone. Researchers found that individuals with high levels of the so-called "dark triad" traits—narcissism, psychopathy, and Machiavellianism—were consistently rated as more trustworthy. Why? The answer lies in looks. People with high dark triad traits tended to be perceived as more physically attractive—and this perception strongly influenced how trustworthy people believed them to be. Penn Badgley attends the Netflix's "You" Season 5 New York Screening at The Plaza Hotel on April 23, 2025 in New York City. Badgley has previously spoken out about his character in "You" being romanticized... Penn Badgley attends the Netflix's "You" Season 5 New York Screening at The Plaza Hotel on April 23, 2025 in New York City. Badgley has previously spoken out about his character in "You" being romanticized despite his psychopathic tendencies. More Michael Loccisano/WireImage)/Getty Images In four experiments involving nearly 600 participants, individuals were asked to judge strangers' faces in rating tasks and simulated trust games. Time and again, those with high dark triad scores were seen as more trustworthy from their image alone. Psychopathy, characterized by a lack of empathy and impulsivity, might seem like it would repel trust. But in practice, individuals with this trait can be highly charming and socially strategic. Similarly, narcissists often exhibit confidence, charm, and polished self-presentation, while Machiavellians excel at reading social cues and manipulating perceptions. The study found that these traits may influence their facial expressions and appearance in subtle ways that boost their appeal, especially in brief or superficial encounters. "In short-term cooperative settings, individuals with high Dark Triad traits tend to inspire more trust, partly due to being seen as more attractive based on their facial features," said paper lead and psychologist professor Qi Wu of the Hunan Normal University, China, in a statement. Notably, their faces still prompt greater trust even when other traits like dominance, extraversion, and attractiveness are accounted for, suggesting facial features have a unique influence on how trustworthy people are perceived." Psychology professor Jason Walker of Chicago's Adler University—who studies the dark triad—told Newsweek: "We're hardwired to associate attractiveness with trust, a psychological shortcut known as the halo effect. "This becomes quite dangerous when it collides with the 'dark triad' personalities, who often know and use it to their advantage. These individuals will present as polished, confident, and even charming. "They have mastered the art of performance: they know how to look like the ideal high-performing teammate or a visionary leader, but they're actually consolidating power and manipulating people's perception." These findings could help explain real-world patterns too, like how people with dark personality traits rise quickly in leadership roles or gain social influence, at least in the short term. Dark Triad Traits in Popular Culture The study may also add context to cultural phenomena like the public fascination with serial killers. For example, Ted Bundy and Jeffrey Dahmer were both described as attractive or charismatic—qualities that may have helped them avoid suspicion. It's playing out in pop culture too. The popular Netflix series YOU, has presented a chilling case study in how charm and appearance can mask deeply violent behavior. The show's central character, Joe Goldberg, is a soft-spoken bookstore manager who also happens to be a stalker and serial killer. Despite this, fans have often expressed romantic interest in him, a reaction actor Penn Badgley has repeatedly pushed back on, reminding viewers: "He is a murderer." While recent research suggests people with high dark triad traits may be perceived as more trustworthy due to their facial features, a 2018 study revealed there are limits to our ability to actually detect those traits. The researchers also tested whether people could identify narcissism, psychopathy, or Machiavellianism just by looking at faces—and the results were mixed. Participants could reliably spot high narcissism in both men and women, and high psychopathy in men. But they struggled to detect psychopathy in women and couldn't recognize Machiavellianism at all. These findings suggest that while some dark triad cues may subtly show in facial appearance—particularly narcissism—the connection isn't consistent across traits or genders. Still, the perception of trustworthiness or attractiveness tied to these faces may explain how people high in dark triad traits can initially gain others' trust, even if the observer can't consciously identify what feels "off." When it comes to protecting yourself from being taken in by dark triad personalities, Walker said: "Watch how they treat those with less power. True character is revealed in how someone engages with people they don't need to impress. Attractiveness may open the door, but sustained trust should be earned through consistency, humility, and integrity, not charisma or a curated image." References Shiramizu, V. K. M., Kozma, L., DeBruine, L. M., & Jones, B. C. (2019). Are dark triad cues really visible in faces? Personality and Individual Differences, 139, 214–216. Zhang, S., Wu, Q., Liu, J., Peng, K., Liang, Y., & Li, H. (2025). Trust in Darkness: Individuals with high dark triad traits gain others' trust through facial attractiveness and other associated facial features. Personality and Individual Differences, 242, 113214.
Yahoo
08-05-2025
- Business
- Yahoo
STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference
HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ('STRATA' or the 'Company') (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019. President and Chief Executive Officer Dr. Dolev Rafaeli will be hosting one-on-one meetings on May 14, 2025 from 9:00 AM to 3:00 PM (ET). To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@ About STRATA Skin Sciences, Inc. STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System. STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA's popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice. Safe Harbor This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company's plans, objectives, expectations and intentions and may contain words such as 'will,' 'may,' 'seeks,' and 'expects,' that suggest future events or trends. These statements, the Company's ability to launch and sell products recently acquired or to be developed in the future, the Company's ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company's ability to build a leading franchise in dermatology and aesthetics, are based on the Company's current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company's expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at and Investor Contact:CORE IR516-222-2560IR@
Yahoo
08-05-2025
- Business
- Yahoo
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference
HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the 'Company'), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019. Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer, will be hosting one-on-one meetings on May 14, 2025 from 9:00 AM to 3:00 PM (ET). To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@ About Plus TherapeuticsHeadquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit About CNSide Diagnostic, LLCCNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide™, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide™ CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases. The Company is planning to commercialize CNSide™ in the U.S. in 2025. Cautionary Statement Regarding Forward-Looking StatementsThis press release contains statements that may be deemed 'forward-looking statements' within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as 'expect' 'potential,' 'anticipating,' 'planning' and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential promise of REYOBIQ™, expectations as to the Company's future performance, including the next steps in developing the Company's product candidates; the Company's clinical trials, including statements regarding the timing and characteristics of the ReSPECT-LM single dose and multi-dose clinical trials; the continued evaluation of rhenium (186Re) obisbemeda including through evaluations in additional patient cohorts. The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company's product candidates and therapies; the results of the Company's research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company's liquidity and capital resources and its ability to raise additional cash; the outcome of the Company's partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company's clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company's operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics' business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics' annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC's website at Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so. Investor ContactCORE IRinvestor@
